le Roux 2024 — Survodutide Phase 2 Obesity Trial

The Lancet Diabetes & Endocrinology

Carel W. le Roux, et al.

Summary

Survodutide showed clinically meaningful body-weight reduction in adults with obesity, supporting further late-stage obesity development.

Study Details

Study Design

Randomized double-blind placebo-controlled phase 2 trial

Indication

Obesity

Intervention

Once-weekly survodutide vs placebo

Species

Human

Sample Size

387 subjects

Risk of Bias Assessment

Sponsor-funded phase 2